enGene (NASDAQ:ENGN) Issues Earnings Results

Key Points

• enGene reported a quarterly loss of $0.47 per share, matching analysts’ consensus estimate.
• The stock opened at $1.82, near its 52-week low of $1.40 and well below its 52-week high of $12.25; institutional investors and hedge funds own 64.16% of shares.
• Analyst sentiment is mixed but leans cautious: enGene has a consensus “Hold” rating, an average price target of $11.05, and recent price-target cuts from several firms.

enGene (NASDAQ:ENGN - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.47) earnings per share for the quarter, meeting the consensus estimate of ($0.47), FiscalAI reports.

enGene Price Performance

Shares of NASDAQ ENGN opened at $1.82 on Tuesday. enGene has a 1 year low of $1.40 and a 1 year high of $12.25. The firm's 50-day moving average is $1.82 and its 200-day moving average is $4.11. The company has a current ratio of 12.57, a quick ratio of 12.57 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $121.92 million, a PE ratio of -0.84 and a beta of -0.28.

Hedge Funds Weigh In On enGene

Several large investors have recently bought and sold shares of the business. Cresset Asset Management LLC acquired a new stake in enGene during the 2nd quarter worth $36,000. Paloma Partners Management Co acquired a new position in shares of enGene in the 2nd quarter valued at $38,000. Raymond James Financial Inc. lifted its stake in shares of enGene by 383.6% in the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company's stock valued at $68,000 after purchasing an additional 7,932 shares during the period. Citadel Advisors LLC lifted its stake in shares of enGene by 153.3% in the 3rd quarter. Citadel Advisors LLC now owns 58,370 shares of the company's stock valued at $399,000 after purchasing an additional 35,327 shares during the period. Finally, Millennium Management LLC boosted its position in shares of enGene by 57.3% in the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company's stock worth $140,000 after purchasing an additional 7,472 shares during the last quarter. 64.16% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of enGene from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 15th. Weiss Ratings reissued a "sell (e+)" rating on shares of enGene in a report on Wednesday, August 12th. Morgan Stanley cut shares of enGene from an "equal weight" rating to an "underweight" rating and set a $3.00 price objective for the company. in a research report on Thursday, June 18th. HC Wainwright reduced their price objective on enGene from $6.00 to $4.00 and set a "buy" rating on the stock in a report on Tuesday, June 16th. Finally, UBS Group decreased their price objective on enGene from $9.00 to $2.00 and set a "neutral" rating on the stock in a research report on Thursday, May 14th. Four equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, enGene currently has a consensus rating of "Hold" and an average price target of $11.05.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.